| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Yadanzioside A targets the InhA enzyme (Mycobacterium enoyl acyl carrier protein reductase), which is a key enzyme in the fatty acid synthesis pathway of Mycobacterium tuberculosis. It also inhibits the JAK2/STAT3 signaling pathway, which is crucial for the regulation of cell growth and survival. Additionally, it targets specific molecular pathways involved in protein synthesis and apoptosis induction in cancer cells.
|
|---|---|
| ln Vitro |
Yadanzioside A exhibits significant antitumor activity, especially against pancreatic cancer cell lines PANC-1 and SW1990. In vitro studies have shown that it induces apoptosis in various cancer cell lines including breast (MCF-7) and liver (HepG2) cancer cells through the activation of intrinsic pathways leading to caspase activation. The compound demonstrates certain antitumor activity with IC50 values of 15 µM against MCF-7 cells and 20 µM against HepG2 cells.
|
| ln Vivo |
In vivo activity data for Yadanzioside A are limited in the available literature. As a quassinoid compound with potent in vitro antitumor activity, it is expected to exhibit efficacy in preclinical tumor models. Further studies are needed to fully characterize its pharmacokinetic and pharmacodynamic profiles in animal models. The compound has been studied for its potential as an anti-tuberculosis drug.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for Yadanzioside A typically involves measuring its inhibitory activity against the InhA enzyme using a standard spectrophotometric assay. The compound is incubated with the enzyme, the substrate (enoyl-ACP), and the cofactor NADH, and the decrease in NADH absorbance is monitored at 340 nm. The IC50 value is determined from the dose-response curve.
|
| Cell Assay |
The in vitro cellular assay for Yadanzioside A typically involves culturing cancer cell lines such as PANC-1, SW1990, MCF-7, or HepG2 in appropriate growth media. Cells are treated with varying concentrations of the compound for a specified duration (typically 48-72 hours), and cell viability is assessed using standard assays such as SRB or MTT. The antiproliferative effect is quantified by determining the half-maximal inhibitory concentration (IC50).
|
| Animal Protocol |
In vivo animal studies for Yadanzioside A would typically involve the use of mouse xenograft models bearing human pancreatic or other tumors. Tumor-bearing mice would be administered the compound via appropriate routes (e.g., oral gavage or intraperitoneal injection) at various dose levels. Tumor growth inhibition would be monitored over several weeks, and endpoints would include tumor volume measurements, body weight changes, and histopathological analysis of tumor tissues.
|
| ADME/Pharmacokinetics |
Yadanzioside A has a molecular weight of 684.68 g/mol and a molecular formula of C32H44O16. It is soluble in DMSO (40 mg/mL) and ethanol (20 mg/mL). The compound should be stored as a powder at -20°C for up to 3 years and in solvent at -80°C for up to 1 year. Further detailed PK parameters are available from the manufacturer's data sheets.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for Yadanzioside A are not available in the public domain. The compound is intended for research use only and should be handled with appropriate laboratory safety precautions. Standard safety assessments would be required before any clinical application. Researchers should consult the safety data sheet for detailed handling and disposal information.
|
| References | |
| Additional Infomation |
Reports indicate that Java bluegrass contains adandazolidin A, and relevant data is available for reference.
Yadanzioside A is also known as YadanziosideA and is a quassinoid terpenoid extracted from Brucea javanica. It has antipancreatic cancer activity, inhibits the InhA enzyme, and has potential as an anti-tuberculosis drug. The compound is used in research to study the pharmacological properties of quassinoid compounds. It has not yet entered clinical trials and is strictly for preclinical research purposes. The purity is typically ≥98%. |
| Molecular Formula |
C32H44O16
|
|---|---|
| Molecular Weight |
684.6822
|
| Exact Mass |
684.263
|
| CAS # |
95258-15-4
|
| PubChem CID |
72956
|
| Appearance |
White to off-white solid powder
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
48
|
| Complexity |
1380
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
C[C@H]1[C@@H]2C[C@@H]3[C@@]45CO[C@]([C@@H]4[C@H](C(=O)O3)OC(=O)CC(C)C)([C@H]([C@@H]([C@@H]5[C@]2(C=C(C1=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)O)C(=O)OC
|
| InChi Key |
QDQJWSSPAMZRIA-AIWMZPBQSA-N
|
| InChi Code |
InChI=1S/C32H44O16/c1-11(2)6-17(34)48-23-25-31-10-44-32(25,29(42)43-5)26(40)22(39)24(31)30(4)8-14(18(35)12(3)13(30)7-16(31)47-27(23)41)45-28-21(38)20(37)19(36)15(9-33)46-28/h8,11-13,15-16,19-26,28,33,36-40H,6-7,9-10H2,1-5H3/t12-,13-,15+,16+,19+,20-,21+,22+,23+,24+,25+,26-,28+,30-,31+,32+/m0/s1
|
| Chemical Name |
methyl (1R,2S,3R,6R,8S,9S,13S,14R,15R,16S,17R)-15,16-dihydroxy-9,13-dimethyl-3-(3-methylbutanoyloxy)-4,10-dioxo-11-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-11-ene-17-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~73.03 mM)
Ethanol : ~25 mg/mL (~36.51 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (3.65 mM) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.65 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.65 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 1.25 mg/mL (1.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 1.25 mg/mL (1.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 1.25 mg/mL (1.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4605 mL | 7.3027 mL | 14.6054 mL | |
| 5 mM | 0.2921 mL | 1.4605 mL | 2.9211 mL | |
| 10 mM | 0.1461 mL | 0.7303 mL | 1.4605 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
